SCHEDULE: Empery Asset Management Discloses 4.99% Stake in Outlook Therapeutics
Beneficial Ownership Report
Empery Asset Management, along with Ryan M. Lane and Martin D. Hoe, reported a 4.99% beneficial ownership stake in Outlook Therapeutics, Inc., primarily through warrants.
Summary
- Empery Asset Management, LP, Ryan M. Lane, and Martin D. Hoe (collectively, 'Reporting Persons') filed an Amendment No. 1 to Schedule 13G for Outlook Therapeutics, Inc.
- The Reporting Persons beneficially own an aggregate of 2,332,948 shares of Common Stock, representing 4.99% of the class.
- This beneficial ownership includes shares of Common Stock issuable upon the exercise of warrants ('Warrants').
- A 'Blocker' provision in the Warrants prevents the Reporting Persons from exercising them to the extent that their beneficial ownership would exceed 4.99% of the outstanding Common Stock.
- As of the filing's event date, the Reporting Persons were unable to exercise all Warrants due to this 4.99% ownership blocker.
- The percentage of class is calculated based on 44,419,529 shares of Common Stock outstanding as of August 11, 2025, as reported in the Company's Form 10-Q filed on August 14, 2025.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory update.
Positives
- The disclosure of a significant, albeit passive, stake by an institutional investor like Empery Asset Management may signal confidence in Outlook Therapeutics' long-term prospects.
Negatives
- The 'Blocker' provision limits the Reporting Persons' ability to increase their ownership beyond 4.99% through warrant exercise, potentially restricting their influence or full participation in future upside if they hold warrants for more shares.
Risks
- The value of the beneficial ownership is tied to the performance of Outlook Therapeutics' common stock, which is subject to market fluctuations and company-specific risks.
Future Outlook
This filing is a beneficial ownership report and does not contain forward-looking statements or guidance from Outlook Therapeutics, Inc. regarding its future performance or operations.
Industry Context
This filing represents a standard disclosure of passive beneficial ownership by an institutional investor in a publicly traded company. It does not provide specific insights into broader industry trends or competitive landscape beyond the investor's decision to hold a stake in Outlook Therapeutics.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which could influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2025-08-11 | Date as of which 44,419,529 shares of Common Stock were outstanding, used for percentage calculation. |
| 2025-08-14 | Date Outlook Therapeutics, Inc. filed its Quarterly Report on Form 10-Q, reporting outstanding shares. |
| 2025-09-30 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-10-21 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Outlook Therapeutics, Empery Asset Management, Beneficial Ownership, Schedule 13G, Warrants, Common Stock, Investment Management, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.